Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.65 USD
−4.13 M USD
2.54 M USD
1.25 M
About Xenetic Biosciences, Inc.
Sector
CEO
James F. Parslow
Headquarters
Framingham
Website
Founded
2011
FIGI
BBG0028WJXC0
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of XBIO is 4.49 USD — it has increased by 5.95% in the past 24 hours. Watch Xenetic Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Xenetic Biosciences, Inc. stocks are traded under the ticker XBIO.
XBIO stock has risen by 12.78% compared to the previous week, the month change is a 11.93% rise, over the last year Xenetic Biosciences, Inc. has showed a 25.42% increase.
XBIO reached its all-time high on Jan 31, 2014 with the price of 39,603.96 USD, and its all-time low was 2.40 USD and was reached on Dec 28, 2022. View more price dynamics on XBIO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
XBIO stock is 10.06% volatile and has beta coefficient of −0.32. Track Xenetic Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Xenetic Biosciences, Inc. there?
Today Xenetic Biosciences, Inc. has the market capitalization of 6.48 M, it has increased by 8.74% over the last week.
Yes, you can track Xenetic Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Xenetic Biosciences, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
XBIO earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.14 USD resulting in a −100.00% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Xenetic Biosciences, Inc. earnings.
Xenetic Biosciences, Inc. revenue for the last quarter amounts to 614.24 K USD, despite the estimated figure of 750.00 K USD. In the next quarter, revenue is expected to reach 230.00 K USD.
XBIO net income for the last quarter is −436.67 K USD, while the quarter before that showed −1.27 M USD of net income which accounts for 65.72% change. Track more Xenetic Biosciences, Inc. financial stats to get the full picture.
No, XBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 4.00 employees. See our rating of the largest employees — is Xenetic Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Xenetic Biosciences, Inc. EBITDA is −4.36 M USD, and current EBITDA margin is −177.79%. See more stats in Xenetic Biosciences, Inc. financial statements.
Like other stocks, XBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Xenetic Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Xenetic Biosciences, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Xenetic Biosciences, Inc. stock shows the neutral signal. See more of Xenetic Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.